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Fibromyalgia( FM) is a chronic syndrome characterized by not only widespread musculoskeletal pain, but
also  many psychological symptoms, including disrupted or non-restorative sleep, fatigue, stiffness, mood
disorders and cognitive impairment [1]. 
The DSM-5 criteria for somatic symptom disorder could be applied to FM [2], even though there is a risk of
assigning a diagnosis of mental illness to a large proportion of patients with a physical chronic illness [3].
Furthermore, the DSM approach to somatisation does not consider important features concerning psycholo-
gical factors that affect physical conditions and abnormal illness behaviours, which might be relevant for
diagnostic and therapeutic processes [3]. Among psychological factors it has also to be noted that some au-
thors consider FM a stress-related syndrome [4] and there are several studies on the role of trauma and
stressful events in FM aetiology [5-7] .
The concept of allostasis emphasizes that healthy functioning requires continual adjustments to the internal
physiological milieu [8].  Allostatic load reflects the cumulative effects of stressful experiences on daily life.
When the cost of chronic exposure to fluctuating or heightened neural or neuroendocrine responses exceeds
the coping resources of an individual, allostatic overload ensues [8].   Clinical criteria for the determination
of allostatic overload have been developed [9]. They are based on: (a) the presence of an identifiable source
of distress  in the form of life events and/or chronic stress exceeding individual coping skills; (b) clinical
manifestations of distress and/or impairment in well-being.  Such criteria, which are part of the revised ver-
sion of the Diagnostic Criteria for Psychosomatic Research (DCPR-R),  have been used in a number of in-
vestigations: they have been found to entail clinical and prognostic implications and to be  associated with al-
terations of biological markers [9].
The aim of this preliminary study is to evaluate the prevalence of allostatic overload in a sample of FM out -
patients using DCPR-Revised criteria.
Participants in this study were diagnosed with FM by a rheumatologist and were regularly visited by a psy-
chiatrist, which is the standard clinical practice in our hospital outpatient unit. The study was approved by
the Institutional Ethics Committee, and only subjects who provided informed consent were included. So-
cio-demographic and clinical data (pain, depression, anxiety, asthenia, sleep disturbances, cognitive impair-
ment, duration of FM and medication) were systematically recorded, and the DCPR-R was used to assess the
psychosomatic syndromes. 
The study population consisted 104 female FM patients. Their socio-demographic and clinical characteristics
are reported in Table 1. The presence of at least one DCPR-R psychosomatic syndrome was found in 78%
(n=81) of the patients, whereas two or more syndromes were found in 31% (n=32).  Allostatic overload oc-
curred in a quarter of patients (table 1); other common DCPR diagnoses were persistent somatization, func-
tional somatic symptoms secondary to a psychiatric disorder and alexithymia (see Table 1).  Nearly all the
patients received pharmacological treatment, as shown in detail in Table 1. The most commonly prescribed
drugs were antidepressants (especially SNRIs, as recommended in current practice), often combined with
benzodiazepines, antiepileptic drugs (prescribed by the psychiatrist) or opioids (prescribed by the rheumato-
logist). The use of supplements was also common. 
In FM patients in our study, the revised version of DCPR seemed to be rapid and simple to use,  guiding the
clinicians through the diagnostic process, confirming previous findings obtained with the previous version of
DCPR [10]. The presence of a DCPR-R syndrome in approximately 80% of the patients interviewed seems
to confirm the importance of investigating psychosomatic factors and to suggest the appropriateness of con-
sidering coexisting psychosocial issues in these patients to fully capture the complexity of the aetiology and
progression of FM.  A better understanding of allostatic overload could therefore influence on the therapeutic
process; for example psychotherapy could focus on the patient's perception of the environment as exceeding
his/her resources or on lifestyle modification. 
Finally, considering that medications are commonly used in FM, and can reduce pain but are often not fully
satisfactory, a better understanding of the coexisting psychosomatic factors can also help increase respons-
iveness to drugs and avoid excessive side effects. This integration of psychological care into the treatment of
physical symptoms can increase adherence to drug regimens and improve the outcome and overall quality of
life.
There were several limitations of this study, such as the lack of information about the psychosocial function -
ing of the patients, the lack of a standardized psychiatric assessment, the lack of biological markers related to
DCPR syndromes and the limited size of the study population considered. For this reason, additional studies
with larger sample sizes are needed to support the proposal of using the DCPR-R as a complementary tool in
the diagnostic work-up and treatment decision-making for FM patients. 
Nevertheless, these results point to the potential for allostatic overload  to expand the clinician's understand-
ing of FM patient vulnerability by providing information on additional elements that do not fit into the tradi-
tional classifications. Further, it may unravel pathophysiological links between environmental circumstances,
inflammation and sensitivity to pain [8].  Of interest is also the fact that persistent somatization (patients in
whom somatic symptoms have clustered, probably due to an enhanced general sensitivity to pain and dis-
comfort) occurred in half of the  patients (table 1) and mood and anxiety disorders had a primary role only
about  a quarter of cases (Table 1).  Therefore, the use of the DCPR-R [9] may help improve the recognition
and characterization of these patients, and it may allow the identification of subgroups with unique features.
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Table 1. Characteristics of FM patients, DCPR-R syndromes distribution and medications and supplements 
prescribed.
Socio-demographic and clinical characteristics of patients
Age 54.5±10.9 years
Education 12±4.1 mean years
Stable partner 71.9%
Stable employment 56.3%
Duration of FM 4.5±3.5 years
Pain 95.3%
Fatigue 78.1%
Sleep disturbances 46.9%
Depression 57.8%
Anxiety 62.5%
Fibrofog 70.3%
Asthenia 78.1%
DCPR-R syndromes Frequency n (%)
Persistent somatization 54 (51.6) 
Allostatic overload 26 (25)
Functional somatic symptoms secondary to a psychiatric disorder 24 (23.3)
Alexithymia 23 (21.9)
Demoralization 11 (10.9)
Conversion symptoms 10 (9.4)
Type A behavior 8 (7.8)
Health anxiety 5 (4.7)
Irritable mood 3 (3.1)
Other diagnosis 4 (3.6)
Medication(s) Frequency n (%)
AD + BDZ 24 (23.1) 
AD 13 (12.5)
AD + AED 10 (9.6)
AD + AED + OP 10 (9.6)
AD + AED + BDZ 10 (9.6)
AD + BDZ + OP 9 (8.7)
Other polytherapy 23 (22.1)
None 5 (4.8)
Supplements 46 (44.3)
 Notes: AD, antidepressants; BDZ, benzodiazepines; AED, anti-epileptic drugs; OP, opioids.
